Claims
- 1. An antiandrogenic compound of the molecular formula:
- 2. The antiandrogenic compound of claim 1 wherein R4 or R4′ is cyanide.
- 3. The antiandrogenic compound of claim 2 having the following molecular formula:
- 4. The antiandrogenic compound of claim 1 having the following molecular structure:
- 5. The antiandrogenic compound of claim 1 having the following molecular structure:
- 6. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a therapeutically effective amount of at least one antiandrogenic compound of the molecular formula:
- 7. The pharmaceutical composition of claim 6 wherein R4 or R4′ is cyanide.
- 8. The pharmaceutical composition of claim 7 having the following molecular formula:
- 9. The pharmaceutical composition of claim 6 having the following molecular structure:
- 10. The pharmaceutical composition of claim 11 having the following molecular structure:
- 11. The pharmaceutical composition of claim 6 wherein said diluent or carrier is suitable for topical application.
- 12. The pharmaceutical composition of claim 6 wherein said diluent or carrier is suitable for oral administration.
- 13. A method of treating, or reducing the risk of developing prostate cancer, comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of the antiandrogenic compound or pharmaceutical composition of any of claims 1-4, 6-9 or 12.
- 14. The method of claim 13, further comprising administering to said patient a therapeutically effective amount of at least one inhibitor selected from the group comprising an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 15. The method of claim 14, wherein an inhibitor of 5α-reductase and an inhibitor of type 5 17β-hydroxysteroid dehydrogenase are administered.
- 16. The method of claim 14, wherein an inhibitor of 5α-reductase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1 are administered.
- 17. The method of claim 14, wherein an inhibitor of type 5 17β-hydroxysteroid dehydrogenase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 18. The method of claim 13, further comprising administering to said patient therapeutically effective amounts of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 19. A method of treating, or reducing the risk of developing, benign prostatic hyperplasia comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of the antiandrogenic compound or pharmaceutical composition of any of claims 1-4, 6-9 or 12.
- 20. The method of claim 19, further comprising administering to said patient a therapeutically effective amount of at least one inhibitor selected from the group comprising an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 21. The method of claim 20, wherein an inhibitor of 5α-reductase and an inhibitor of type 5 17β-hydroxysteroid dehydrogenase are administered.
- 22. The method of claim 20, wherein an inhibitor of 5α-reductase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1 are administered.
- 23. The method of claim 20, wherein an inhibitor of type 5 17β-hydroxysteroid dehydrogenase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 24. The method of claim 19, further comprising administering to said patient therapeutically effective amounts of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 25. A method of treating, or reducing the risk of developing, polycystic ovarian syndrome comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of the antiandrogenic compound or pharmaceutical composition of any of claims 1-4, 6-9 or 12.
- 26. The method of claim 25, further comprising administering to said patient a therapeutically effective amount of at least one inhibitor selected from the group comprising an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 27. The method of claim 26, wherein an inhibitor of 5αx-reductase and an inhibitor of type 5 17β-hydroxysteroid dehydrogenase are administered.
- 28. The method of claim 26, wherein an inhibitor of 5α-reductase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1 are administered.
- 29. The method of claim 26, wherein an inhibitor of type 5 17β-hydroxysteroid dehydrogenase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 30. The method of claim 25, further comprising administering to said patient therapeutically effective amounts of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 31. A method of treating precocious puberty comprising administering to a patient in need of such treatment a therapeutically effective amount of the antiandrogenic compound or pharmaceutical composition of any of claims 1-4, 6-9 or 12.
- 32. The method of claim 31, further comprising administering to said patient a therapeutically effective amount of at least one inhibitor selected from the group comprising an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 33. The method of claim 32, wherein an inhibitor of 5α-reductase and an inhibitor of type 5 17β-hydroxysteroid dehydrogenase are administered.
- 34. The method of claim 32, wherein an inhibitor of 5α-reductase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1 are administered.
- 35. The method of claim 32, wherein an inhibitor of type 5 17β-hydroxysteroid dehydrogenase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 36. The method of claim 31, further comprising administering to said patient therapeutically effective amounts of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 37. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia comprising administering to a patient in need of such treatment or reduction a therapeutically effective amount of the antiandrogenic compounds or pharmaceutical compositions of any of claims 1-3, 5 or of the pharmaceutical composition of any of 10 or 11.
- 38. The method of claim 37, further comprising administering to said patient a therapeutically effective amount of at least one inhibitor selected from the group comprising an inhibitor of type 5 17β(-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 39. The method of claim 38, wherein an inhibitor of 5α-reductase and an inhibitor of type 5 17β-hydroxysteroid dehydrogenase are administered.
- 40. The method of claim 38, wherein an inhibitor of 5α-reductase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1 are administered.
- 41. The method of claim 38, wherein an inhibitor of type 5 17β-hydroxysteroid dehydrogenase and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 42. The method of claim 37, further comprising administering to said patient therapeutically effective amounts of an inhibitor of type 5 17β-hydroxysteroid dehydrogenase, an inhibitor of 5α-reductase inhibitor and an inhibitor of Prostate Short-Chain Dehydrogenase Reductase 1.
- 43. An antiandrogenic compound of the molecular formula:
- 44. The antiandrogenic compound having the following molecular structure:
- 45. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia comprising administering to a patient in need of such treatment or reduction of a therapeutically effective amount of the antiandrogenic compounds of any of claims 1-3, and 5 or of the pharmaceutical composition of any of claims 6, 7, 10 and 11.
RELATED APPLICATION
[0001] This application claims priority of U.S. provisional application No. 60/357,785, filed Feb. 15, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60357785 |
Feb 2002 |
US |